OTL-200 pre-BLA meeting granted for second quarter of 2023 following productive clinical Type B meeting with the U.S. Food and Drug Administration (FDA) .
BOSTON and LONDON, Feb. 27, 2023 Orchard Therapeutics , a global gene therapy leader, today announced it has reached an agreement with the New Therapies Council which will result in reimbursed. | February 27, 2023